Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.310 -0.080 (-5.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Enveric Biosciences Inc. (NASDAQ: ENVB) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Nasdaq Surges 100 Points; Walmart Raises Full-Year Outlook
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.09% to 33,451.95 while the NASDAQ rose 0.79% to 12,599.66. The S&P... 
Via Benzinga
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373
Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative 
Via Spotlight Growth
Topics Derivatives Intellectual Property
Exposures Derivatives Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office for a patent application involving EB-373, th 
Via Benzinga
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Q1 Net Loss Of $4.80M, More On Basic And Diluted Loss Per Share
Enveric Biosciences, Inc. (NASDAQ: ENVB) released its corporate update and reported financial results for the first quarter of 2023 ending March 31, 2023. 
Via Benzinga
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
From Enveric Biosciences, Inc.
Via Business Wire
EXCLUSIVE: Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
Recently, at the Benzinga Psychedelic Capital Conference, leading experts from the biotech and pharmaceutical industry gathered to discuss the remarkable potential of psychedelics in medicine. 
Via Benzinga
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
Via Benzinga
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
From Enveric Biosciences
Via Business Wire
Enveric Creates Subsidiary Down Under To Further Next-Generation Psychedelics Program
Drug development biotech company Enveric Biosciences (NASDAQ: ENVB) has created Australia-based subsidiary Enveric Therapeutics Pty. Ltd. to support the progress of its next-generation psychedelics... 
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Enveric Biosciences: Novel Next-Gen Drug Discovery Platform Includes Rare Toad Enzyme
Biopharma company Enveric Biosciences (NASDAQ: ENVB) has shared new findings involving the first-ever isolation of a specific enzyme from the cane toad, plus the successful development of a... 
Via Benzinga
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
From Enveric Biosciences
Via Business Wire
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
From Enveric Biosciences
Via Business Wire
The 7 Most Promising Psychedelic Stocks to Buy in February
These psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector. 
Via InvestorPlace
Enveric Biosciences to Present at the BIO CEO & Investor Conference
From Enveric Biosciences
Via Business Wire
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.